Pharmacological management of sleep apnoea

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 1, 2006, Pages 11-23

  Abad, Vivien C ^a   Guilleminault, Christian ^b  

^a PALO ALTO MEDICAL FOUNDATION   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

blockers; Intranasal corticosteroids; Mirtazapine; Nasal decongestants; Octreotide; Oestrogen; Sleep apnoea

Indexed keywords

ACETAZOLAMIDE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMOCRIPTINE MESILATE; BUDESONIDE; CARBON DIOXIDE; CORTICOSTEROID; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAPRAM; ESTROGEN; FLUTICASONE; GLUTAMATE RECEPTOR ANTAGONIST; GROWTH HORMONE; METHYLXANTHINE DERIVATIVE; MODAFINIL; NALOXONE; NALTREXONE; NICOTINE; OPIATE ANTAGONIST; OXYGEN; PHYSOSTIGMINE; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; THEOPHYLLINE; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ABDOMINAL PAIN; ACIDOSIS; ACNE; ACROMEGALY; ANGIONEUROTIC EDEMA; ANXIETY DISORDER; ASTHENIA; BEHAVIOR MODIFICATION; BLEEDING; BLOOD CLOTTING DISORDER; BODY POSTURE; BODY WEIGHT DISORDER; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DYSGEUSIA; EDEMA; EJACULATION DISORDER; EMOTIONAL DISORDER; EPISTAXIS; FATIGUE; FLUSHING; GYNECOMASTIA; HEALTH HAZARD; HEART ARRHYTHMIA; HEART BLOCK; HIRSUTISM; HUMAN; HYPERCAPNIA; HYPERTENSION; HYPERTHYROIDISM; HYPOGONADISM; HYPOTENSION; IMPOTENCE; INFECTION; INJECTION SITE REACTION; INSOMNIA; INVOLUNTARY MOVEMENT; IRRITABILITY; LIBIDO DISORDER; MASTALGIA; MENSTRUATION DISORDER; MENTAL INSTABILITY; METABOLIC DISORDER; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MYALGIA; NAUSEA; NEUTROPENIA; NIGHTMARE; PARANASAL SINUS DISEASE; PARESTHESIA; PHARYNGITIS; POLYCYTHEMIA; POLYURIA; POSITIVE END EXPIRATORY PRESSURE; PROTEINURIA; REVIEW; RHINITIS; RISK REDUCTION; SALIVATION DISORDER; SEBORRHEA; SEIZURE; SKIN MANIFESTATION; SLEEP APNEA SYNDROME; SLEEP AROUSAL DISORDER; SLEEP DISORDER; SOMNOLENCE; SUPRAVENTRICULAR TACHYCARDIA; SURGICAL TECHNIQUE; SWEAT GLAND DISEASE; TINNITUS; TREMOR; URINARY HESITANCY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; SLEEP APNEA SYNDROMES;

EID: 30344487535     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.1.11     Document Type: Review

References (88)

1. YOUNG T, PEPPARD PE, GOTTLIEB DJ: Epidemiology of obstructive sleep apnea: a population health perspective. Am. J. Respir. Crit. Care Med. (2002) 165(9):1217-1239.
2. DURAN J, ESNAOLA S, RUBIO R, IZTUETA A: Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am. J. Respir. Crit. Care Med. (2001) 163(3 Pt 1):685-689.
3. BIXLER EO, VGONTZAS AN, TEN HAVE T, TYSON K, KALES A: Effects of age on sleep apnea in men: I. Prevalence and severity. Am. J. Respir. Crit. Care Med. (1998) 157(1):144-148.
4. BIXLER EO, VGONTZAS AN, LIN HM et al.: Prevalence of sleep-disordered breathing in women: effects of gender. Am. J. Respir. Crit. Care Med. (2001) 163(3 Pt 1):608-613.
5. FERINI-STRAMBI L, FANTINI ML, CASTRONOVO C: Epidemiology of obstructive sleep apnea syndrome. Minerva Med. (2004) 95(3):187-202.
6. ABAD VC, GUILLEMINAULT C: Central sleep apnea. In: Sleep and its Disorders. Handbook of Clinical Neurophysiology (Volume 60). Guilleminault C (Ed.) Elsevier, Philadelphia, USA (2005):207-221.
7. CANOVA CR, DOWNS SH, KNOBLAUCH A, ANDERSSON M, TAMM M, LEUPPI JD: Increased prevalence of perennial allergic rhinitis in patients with obstructive sleep apnea. Respiration (2004) 71(2):138-143.
8. KIELY JL, NOLAN P, MCNICHOLAS WT: Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax (2004) 59(1):50-55.
9. BROUILLETTE RT, MANOUKIAN JJ, DUCHARME FM et al.: Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea. J. Pediatr. (2001) 138(6):838-844.
10. MANSFIELD LE, DIAZ G, POSEY CR, FLORES-NEDER J: Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann. Allergy Asthma Immunol. (2004) 92(2):240-244.
11. BRAVER HM, BLOCK AJ: Effect of nasal spray, positional therapy, and the combination thereof in the asymptomatic snorer. Sleep (1994) 17(6):516-521.
12. GOTHE B, STROHL KP, LEVIN S, CHERNIACK NS: Nicotine: a different approach to treatment of obstructive sleep apnea. Chest (1985) 87(1):11-17.
13. DAVILA DG, HURT RD, OFFORD KP, HARRIS CD, SHEPARD JW JR: Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am. J. Respir. Crit. Care Med. (1994) 150(2):469-474.
14. ZEVIN S, SWED E, CAHAN C: Clinical effects of locally delivered nicotine in obstructive sleep apnea syndrome. Am. J. Ther. (2003) 10(3):170-175.
15. FERBER C, DUCLAUX R, MOURET J: Naltrexone improves blood gas patterns in obstructive sleep apnoea syndrome through its influence on sleep. J. Sleep Res. (1993) 2(3):149-155.
16. GUILLEMINAULT C, HAYES B: Naloxone, theophylline, bromocriptine, and obstructive sleep apnea. Negative results. Bull. Eur. Physiopathol. Respir. (1983) 19:632-634.
17. ATKINSON RL, SURATT PM, WILHOIT SC, RECANT L: Naloxone improves sleep apnea in obese humans. Int. J. Obes. (1985) 9(4):233-239.
18. GREENBERG HE, RAPOPORT DM, ROTHENBERG SA, KANENGISER LA, NORMAN RG, GOLDRING RM: Endogenous opiates modulate the postapnea ventilatory response in the obstructive sleep apnea syndrome. Am. Rev. Respir. Dis. (1991) 143(6):1282-1287.
19. HU K, LI Q, YANG J, HU S, CHEN X: The effect of theophylline on sleep-disordered breathing in patients with stable chronic congestive heart failure. Chin. Med. J. (2003) 116(11):1711-1716.
20. JAVAHERI S, PARKER TJ, WEXLER L, LIMING JD, LINDOWER P, ROSELLE GA: Effect of theophylline on sleep-disordered breathing in heart failure. N. Engl. J. Med. (1996) 335(8):562-567.
21. ESPINOZA H, ANTIC R, THORNTON AT, MCEVOY RD: The effects of aminophylline on sleep and sleep-disordered breathing in patients with obstructive sleep apnea syndrome. Am. Rev. Respir. Dis. (1987) 136(1):80-84.
22. SALETU B, OBERNDORFER S, ANDERER P et al.: Efficiency of continuous positive airway pressure versus theophylline therapy in sleep apnea: comparative sleep laboratory studies on objective and subjective sleep and awakening quality. Neuropsychobiology (1999) 39(3):151-159.
23. MULLOY E, MCNICHOLAS WT: Theophylline in obstructive sleep apnea. A double-blind evaluation. Chest (1992) 101:753-757.
24. CHARDON K, BACH V, TELLIEZ F et al.: Effect of caffeine on peripheral chemoreceptor activity in premature neonates: interaction with sleep stages. J. Appl. Physiol. (2004) 96(6):2161-2166.
25. DE CAROLIS MP, ROMAGNOLI C, MUZII U et al.: Pharmacokinetic aspects of caffeine in premature infants. Dev. Pharmacol. Ther. (1991) 16(3):117-122.
26. CURZI-DASCALOVA L, AUJARD Y, GAULTIER C, RAIGURU M: Sleep organization is unaffected by caffeine in premature infants. J. Pediatr. (2002) 140(6):766-771.
27. BAIRAM A, BOUTROY MJ, BADONNEL Y, VERT P: [The choice between theophylline and caffeine in the treatment of apnea in premature infants] Arch. Fr. Pediatr. (1990) 47(6):461-465.
28. SURATT PM, WILHOIT SC, BROWN ED, FINDLEY LJ: Effect of doxapram on obstructive sleep apnea. Bull. Eur. Physiopathol. Respir. (1986) 22(2):127-131.
29. YOUNG T, FINN L, AUSTIN D, PETERSON A: Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. Am. J. Respir. Crit. Care Med. (2003) 167(9):1181-1185.
30. MANBER R, KUO TF, CATALDO N, COLRAIN IM: The effects of hormone replacement therapy on sleep-disordered breathing in postmenopausal women: a pilot study. Sleep (2003) 26(2):163-168.
31. POLO-KANTOLA P, RAUHALA E, HELENIUS H, ERKKOLA R, IRJALA K, POLO O: Breathing during sleep in menopause: a randomized, controlled, crossover trial with estrogen therapy. Obstet. Gynecol. (2003) 102(1):68-75.
32. BLOCK AJ, WYNNE JW, BOYSEN PG, LINDSEY S, MARTIN C, CANTOR B: Menopause, medroxyprogesterone and breathing during sleep. Am. J. Med. (1981) 70(3):506-510.
33. COOK WR, BENICH JJ, WOOTEN SA: Indices of severity of obstructive sleep apnea syndrome do not change during medroxyprogesterone acetate therapy. Chest (1989) 96(2):262-266.
34. STROHL KP, HENSLEY MJ, SAUNDERS NA, SCHARF SM, BROWN R, INGRAM RH JR: Progesterone administration and progressive sleep apneas. JAMA (1981) 245(12):1230-1232.
35. COLLOP NA: Medroxyprogesterone acetate and ethanol-induced exacerbation of obstructive sleep apnea. Chest (1994) 106(3):792-799.
36. RAJAGOPAL KR, ABBRECHT PH, JABBARI B: Effects of medroxyprogesterone acetate in obstructive sleep apnea. Chest (1986) 90(6):815-821.
37. CISTULLI PA, BARNES DJ, GRUNSTEIN RR, SULLIVAN CE: Effect of short-term hormone replacement in the treatment of obstructive sleep apnoea in postmenopausal women. Thorax (1994) 49(7):699-702.
38. SCHNEIDER BK, PICKETT CK, ZWILLICH CW et al.: Influence of testosterone on breathing during sleep. J. Appl. Physiol. (1986) 61(2):618-623.
39. LIU PY, YEE B, WISHART SM et al.: The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J. Clin. Endocrinol. Metab. (2003) 88(8):3605-3613.
40. STEWART DA, GRUNSTEIN RR, BERTHON-JONES M, HANDELSMAN DJ, SULLIVAN CE: Androgen blockade does not affect sleep-disordered breathing or chemosensitivity in men with obstructive sleep apnea. Am. Rev. Respir. Dis. (1992) 146(6):1389-1393.
41. LIN CC, TSAN KW, CHEN FJ: The relationship between sleep apnea syndrome and hypothyroidism. Chest (1992) 102(6):1663-1667.
42. RESTA O, PANNACCIULLI N, DI GIOIA G, STEFANO A, BARBARO MP, DE PERGOLA G: High prevalence of previously unknown subclinical hypothyroidism in obese patients referred to a sleep clinic for sleep disordered breathing. Nutr. Metab. Cardiovasc. Dis. (2004) 14(5):248-253.
43. HUDGEL DW, THANAKITCHARU S: Pharmacologic treatment of sleep-disordered breathing. Am. J. Respir. Crit. Care Med. (1998) 158(3):691-699.
44. MAGALANG UJ, MADOR MJ: Behavioral and pharmacologic therapy of obstructive sleep apnea. Clin. Chest Med. (2003) 24(2):343-353.
45. RAJAGOPAL KR, ABBRECHT PH, DERDERIAN SS et al.: Obstructive sleep apnea in hypothyroidism. Ann. Intern. Med. (1984) 101(4):491-494.
46. HIRA HS, SIBAL L: Sleep apnea syndrome among patients with hypothyroidism. J. Assoc. Physicians India (1999) 47(6):615-618.
47. GRUNSTEIN RR, SULLIVAN CE: Sleep apnea and hypothyroidism: mechanisms and management. Am. J. Med. (1988) 85(6):775-779.
48. BLANCO PEREZ JJ, BLANCO-RAMOS MA, ZAMARRON SANZ C, SOUTO FERNANDEZ A, MATO MATO A, LAMELA LOPEZ J: Acromegaly and sleep apnea. Arch. Bronconeumol. (2004) 40(8):355-359.
49. HERRMANN BL, WESSENDORF TE, AJAJ W, KAHLKE S, TESCHLER H, MANN K: Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with Acromegaly. Eur. J. Endocrinol. (2004) 151(3):309-315.
50. ZIEMER DC, DUNLAP DB: Relief of sleep apnea in acromegaly by bromocriptine. Am. J. Med. Sci. (1988) 295(1):49-51.
51. PLANES C, FOUCHER A, LEROY M, DARTOIS N, JUSTE K, BAILLART O, RAFFESTIN B: Effect of celiprolol treatment in hypertensive patients with sleep apnea. Sleep (1999) 22(4):507-513.
52. MAYER J, WEICHLER U, HERRES-MAYER B, SCHNEIDER H, MARX U, PETER JH: Influence of metoprolol and cilazapril on blood pressure and on sleep apnea activity. J. Cardiovasc. Pharmacol. (1990) 16(6):952-961.
53. GROTE L, WUTKEWICZ K, KNAACK L, PLOCH T, HEDNER J, PETER JH: Association between blood pressure reduction with antihypertensive treatment and sleep apnea activity. Am. J. Hypertens. (2000) 13(12):1280-1287.
54. ISSA FG: Effect of clonidine in obstructive sleep apnea. Am. Rev. Respir. Dis. (1992) 145(2 Pt 1):435-439.
55. HEDNER J, GRUNSTEIN R, ERIKSSON B, EJNELL H: A double-blind, randomized trial of sabeluzole - a putative glutamate antagonist - in obstructive sleep apnea. Sleep (1996) 19(4):287-289.
56. FINNIMORE AJ, ROEBUCK M, SAJKOV D, MCEVOY RD: The effects of the GABA agonist, baclofen, on sleep and breathing. Eur. Respir. J. (1995) 8(2):230-234.
57. TORVALDSSON S, GROTE L, PEKER Y, BASUN H, HEDNER J: A randomized placebo-controlled trial of an NMDA receptor antagonist in sleep-disordered breathing. J. Sleep Res. (2005) 14(2):149-155.
58. WHITE DP, ZWILLICH CW, PICKETT CK, DOUGLAS NJ, FINDLEY LJ, WEILl JV: Central sleep apnea. Improvement with acetazolamide therapy. Arch. Intern. Med. (1982) 142(10):1816-1819.
59. DEBACKER WA, VERBRAECKEN J, WILLEMEN M, WITTESAELE W, DECOCK W, VAN DEHEYNING P. Central apnea index decreases after prolonged treatment with acetazolamide. Am. J. Respir. Crit. Care Med. (1995) 151(1):87-91.
60. HACKETT PH, ROACH RC, HARRISON GL, SCHOENE RB, MILLS WJ JR: Respiratory stimulants and sleep periodic breathing at high altitude. Almitrine versus acetazolamide. Am. Rev. Respir. Dis. (1987) 135(4):896-898.
61. SHARP JT, DRUZ WS, D'SOUZA V, DIAMOND E: Effect of metabolic acidosis upon sleep apnea. Chest (1985) 87(5):619-624.
62. TOJIMA H, KUNITOMO F, KIMURA H, TATSUMI K, KURIYAMA T, HONDA Y: Effects of acetazolamide in patients with the sleep apnoea syndrome. Thorax (1988) 43(2):113-119.
63. WHYTE KF, GOULD GA, AIRLIE MA, SHAPIRO CM, DOUGLAS NJ: Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. Sleep (1988) 11(5):463-472.
64. REMMERS JE, DEGROOT WJ, SAUERLAND EK, ANCH AM: Pathogenesis of upper airway occlusion during sleep. J. Appl. Physiol. (1978) 44(6):931-938.
65. BERRY RB, YAMAURA EM, GILL K, REIST C: Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep (1999) 22(8):1087-1092.
66. KRAICZI H, HEDNER J, DAHLOF P, EJNELL H, CARLSON J: Effect of serotonin uptake inhibition on breathing during sleep and daytime symptoms in obstructive sleep apnea. Sleep (1999) 22(1):61-67.
67. HANZEL DA, PROIA NG, HUDGEL DW: Response of obstructive sleep apnea to fluoxetine and protriptyline. Chest (1991) 100(2):416-421.
68. BROWNELL LG, WEST P, SWEATMAN P, ACRES JC, KRYGER MH: Protriptyline in obstructive sleep apnea: a double-blind trial. N. Engl. J. Med. (1982) 307(17):1037-1042.
69. SMITH PL, HAPONIK EF, ALLEN RP, BLEECKER ER: The effects of protriptyline in sleep-disordered breathing. Am. Rev. Respir. Dis. (1983) 127(1):8-13.
70. HEDNER J, KRAICZI H, PEKER Y, MURPHY P: Reduction of sleep-disordered breathing after physostigmine. Am. J. Respir. Crit. Care Med. (2003) 168(10):1246-1251.
71. GUILLEMINAULT C, PHILIP P: Tiredness and somnolence despite initial treatment of obstructive sleep apnea syndrome (what to do when an OSAS patient stays hypersomnolent despite treatment). Sleep (1996) 19(9 Suppl):S117-S122.
72. ARNULF I, HOMEYER P, GARMA L, WHITELAW WA, DERENNE JP: Modafinil in obstructive sleep apnea-hypopnea syndrome: a pilot study in 6 patients. Respiration (1997) 64(2):159-161.
73. HEITMANN J, CASSEL W, GROTE L, BICKEL U, HARTLAUB U, PENZEL T, PETER JH: Does short-term treatment with modafinil affect blood pressure in patients with obstructive sleep apnea? Clin. Pharmacol. Ther. (1999) 65(3):328-335.
74. PACK AI, BLACK JE, SCHWARTZ JR, MATHESON JK: Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am. J. Respir. Crit. Care Med. (2001) 164(9):1675-1681.
75. SCHWARTZ JR, HIRSHKOWITZ M, ERMAN MK, SCHMIDT-NOWARA W: Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest (2003) 124(6):2192-2199.
76. BLACK JE, HIRSHKOWITZ M: Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep (2005) 28(4):464-471.
77. KINGSHOTT RN, VENNELLE M, COLEMAN EL, ENGLEMAN HM, MACKAY TW, DOUGLAS NJ: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am. J. Respir. Crit. Care Med. (2001) 163(4):918-923.
78. VGONTZAS AN, ZOUMAKIS E, LIN HM, BIXLER EO, TRAKADA G, CHROUSOS GP: Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-alpha antagonist. J. Clin. Endocrinol. Metab. (2004) 89(9):4409-4413.
79. HUDGEL DW, HENDRICKS C, DADLEY A: Alteration in obstructive apnea pattern induced by changes in oxygen- and carbon-dioxide-inspired concentrations. Am. Rev. Respir. Dis. (1988) 138(1):16-29.
80. SZOLLOSI I, JONES M, MORRELL MJ, HELFET K, COATS AJ, SIMONDS AK: Effect of CO2 inhalation on central sleep apnea and arousals from sleep. Respiration (2004) 71(5):493-498.
81. BADR MS, GROSSMAN JE, WEBER SA: Treatment of refractory sleep apnea with supplemental carbon dioxide. Am. J. Respir. Crit. Care Med. (1994) 150(2):561-564.
82. 2 in a patient with non-obstructive sleep apnoea. J. Neurol. (1993) 241(1):45-48.
83. FARNEY RJ, WALKER JM, ELMER JC, VISCOMI VA, ORD RJ: Transtracheal oxygen, nasal CPAP and nasal oxygen in five patients with obstructive sleep apnea. Chest (1992) 101(5):1228-1235.
84. CHAUNCEY JB, ALDRICH MS: Preliminary findings in the treatment of obstructive sleep apnea with transtracheal oxygen. Sleep (1990) 13(2):167-174.
85. SMITH PL, HAPONIK EF, BLEECKER ER: The effects of oxygen in patients with sleep apnea. Am. Rev. Respir. Dis. (1984) 130(6):958-963.
86. GOLD AR, BLEECKER ER, SMITH P: A shift from central and mixed sleep apnea to obstructive sleep apnea resulting from low-flow oxygen. Am. Rev. Respir. Dis. (1985) 132(2):220-223.
87. LANDSBERG R, FRIEDMAN M, ASCHER-LANDSBERG J: Treatment of hypoxemia in obstructive sleep apnea. Am. J. Rhinol. (2001) 15(5):311-313.
88. KUSHIDA CA, LITTNER MR, MORGENTHALER T et al: Practice parameters for the indications for polysomnography and related procedures: An update for 2005. Sleep (2005) 28(4):499-521.